Biopharma industry executives talk about what it takes to stay competitive in the most active area of drug development.
ASCO Roundup: Looking For The Future Of Cancer Research
As the American Society of Clinical Oncology annual meeting drew to a close, industry execs discussed staying competitive, adjusting to policy changes and how artificial intelligence is advancing cancer R&D.
More from Business Strategy
More from Scrip
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.